Table 2.

Subset of the preclinical research targeting drug-induced autophagy in various cancers.

Drug Classification	Drug name	Targeting cancer cells	Autophagy inhibitor	References
Natural compounds	Polyphyllin I Ursolic acid Paclitaxel Tetrandrine Pterostilbene Topotecan Cucurbitacin Sulforaphane Honokiol Combretastatin A-4	Hepatoma Prostate cancer Cervical cancer Renal cancer Bladder cancer Various cancers Lung cancer Breast cancer Lung cancer Glioblastoma Neuroblastoma Lung cancer Various cancers	CQ 3-MA 2-deoxyD-glucose 3-MA or BafA1 Obatoclax CQ 3-MA or BafA1 3-MA or BafA1 CQ CQ 3-MA CQ ABT-737, 3-MA or BafA1	(Shi et al., 2015) (Shin et al., 2012; Junco et al., 2015) (Peng et al., 2014) (Zhang et al., 2013) (Jiménez-Guerrero et al., 2018) (Mei et al., 2015) (Hsieh et al., 2013) (Wei-Chih Chen et al., 2014) (Wang Y et al., 2011) (Yuan et al., 2014) (Horwacik et al., 2015) (Lv et al., 2015) (Li et al., 2014)
Tyrosine kinase inhibitor	Imatinib Sorafenib Sunitinib Linifanib Gefitinib Erlotinib Cediranib	Leukemia Glioblastoma Hepatoma Glioblastoma Various cancers Hepatoma Breast cancer Lung cancer Lung cancer Glioblastoma	CQ or Clarithromycin BafA1 3-MA CQ CQ CQ, HCQ or 3-MA HCQ, BafA1 or 3-MA Clarithromycin, EGCG CQ Quinacrine	(Altman and Platanias, 2012; Zeng et al., 2015) (Shingu et al., 2009) (Yuan et al., 2014) (Liu et al., 2016) (Abdel-Aziz et al., 2014) (Pan et al., 2014) (Dragowska et al., 2013; Liu et al., 2017) (Sugita et al., 2015; Meng et al., 2019) (Zou et al., 2013) (Lobo et al., 2013)
Conventional cytotoxic drugs	Cisplatin Oxaliplatin Temozolomide 5-Fluorouracil Cytarabine Doxorubicin Pirarubicin	Lung cancer Ovarian cancer Glioblastoma Gastric cancer Bladder cancer Endometrial cancer Epithelial cancer Colorectal cancer Glioblastoma Cholangiocarcinoma Colon cancer Acute myeloid Hepatoma, osteosarcoma leukemia Osteosarcoma Breast cancer Bladder cancer	3-MA or CQ 3-MA or CQ 3-MA CQ 3-MA or CQ CQ 4-Acetylantroquinonol B 3-MA Resveratrol or CQ Quinacrine Capsaicin 3-MA or CQ Baf A1 or CQ EGCG 3-MA Resveratrol HCQ or 3-MA HCQ or 3-MA	(Wu et al., 2015; Liu et al., 2015) (Zhang et al., 2012; Wang and GS, 2014; Bao et al., 2015) (Zhang et al., 2015) (Zhang et al., 2015) (Ojha et al., 2016) (Fukuda et al., 2015) (Liu et al., 2017) (Liu et al., 2015) (Lin et al., 2012; Yan et al., 2016) (Buccarelli et al., 2018) (Hong et al., 2015) (Sasaki et al., 2010; Li et al., 2010) (Bosnjak et al., 2014) (Chen et al., 2014; Wang and Ding Chen, 2018) (Zhao et al., 2014) (Rai et al., 2016) (Pan et al., 2015) (Li et al., 2015)
Proteasome inhibitor	Carfilzomib	Myeloma	CQ, HCQ	(Jarauta et al., 2016; Baranowska et al., 2016)
	Bortezomib	Myeloma Myeloma	Macrolide antibiotics BafA1, HCQ	(Moriya et al., 2013) (Di Lernia et al., 2020; Miyazawa, 2011)
	Ixazomib	Glioblastoma Colorectal cancer	3-MA ABT-737	(Zhang et al., 2014) (Yang et al., 2016)

CQ, chloroquine; HCQ, hydroxychloroquine; 3-MA, 3-methyladenine; Baf A1, bafilomycin A1; EGCG, Epigallocatechin gallate.